Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors

OBJECTIVE: Fluzoparib (SHR3162) is a novel, potent poly(ADP-ribose) polymerases (PARP)1, 2 inhibitor that showed anti-tumor activity in xenograft models. We conducted a phase I, first-in-human, dose-escalation and expansion (D-Esc and D-Ex) trial in patients with advanced solid cancer. METHODS: This...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Huiping, Liu, Rongrui, Shao, Bin, Ran, Ran, Song, Guohong, Wang, Ke, Shi, Yehui, Liu, Jihong, Hu, Wenjing, Chen, Fu, Liu, Xiaoran, Zhang, Gairong, Zhao, Chuanhua, Jia, Ru, Wang, Quanren, Rugo, Hope S., Zhang, Yifan, Li, Guangze, Xu, Jianming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369176/
https://www.ncbi.nlm.nih.gov/pubmed/32694901
http://dx.doi.org/10.21147/j.issn.1000-9604.2020.03.08

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369176/
https://www.ncbi.nlm.nih.gov/pubmed/32694901
http://dx.doi.org/10.21147/j.issn.1000-9604.2020.03.08

Ejemplares similares